To study the sequential changes of HIF 1α (hypoxia inducible factor 1 alpha) in experimental spinal cord injury in rats and to analyze its potential effects in SCI. Methods: A static compression model of SCI was empl...To study the sequential changes of HIF 1α (hypoxia inducible factor 1 alpha) in experimental spinal cord injury in rats and to analyze its potential effects in SCI. Methods: A static compression model of SCI was employed in this study. Expressions of HIF 1α were measured with immunohistochemical staining, while flow cytometry was used to determine the apoptotic ratio and bcl 2 expre ssions. Results: HIF 1α began to increase 1 day after injury, and rea ched the peak at 3 7 days. Two weeks later, it declined significantly. The sequ ential changes of HIF 1α coincided well with the alterations of apoptotic rat io and contents of bcl 2. Conclusions: HIF 1α possibly participates in the secondary is chemic and hypoxic procedures after spinal cord injury, and may mediate the trau matic apoptosis. Further understanding of HIF 1α may provide new therapeuti c regimens for SCI.展开更多
基金ThisworkwassupportedbyagrantfromtheNationalNaturalScienceFoundationofChina (No .3 9970 75 5 )
文摘To study the sequential changes of HIF 1α (hypoxia inducible factor 1 alpha) in experimental spinal cord injury in rats and to analyze its potential effects in SCI. Methods: A static compression model of SCI was employed in this study. Expressions of HIF 1α were measured with immunohistochemical staining, while flow cytometry was used to determine the apoptotic ratio and bcl 2 expre ssions. Results: HIF 1α began to increase 1 day after injury, and rea ched the peak at 3 7 days. Two weeks later, it declined significantly. The sequ ential changes of HIF 1α coincided well with the alterations of apoptotic rat io and contents of bcl 2. Conclusions: HIF 1α possibly participates in the secondary is chemic and hypoxic procedures after spinal cord injury, and may mediate the trau matic apoptosis. Further understanding of HIF 1α may provide new therapeuti c regimens for SCI.
